arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Silo Pharma, Inc.

SILO
$3.69 ▼ -0.87 (-19.08%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
49 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Silo Pharma, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $50.6M
Dividend Yield
Revenue Growth 0.0%
Op. Margin
ROIC -22.2%
FCF / Share $-0.06
Trailing P/E
Price / Book 10.6x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

49-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$18.03K
— 0.0%
Net Income Profit after all expenses
$-1.65M
↓ -59.7%
FCF / Share Free cash flow per share
$-0.06
↑ +83.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Financial Health
12
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 12 years · 49 quarters